IWGDF Guidelines – Disclosure of interest form

Name: Klaus Kirketerp-Møller

Affiliation: Copenhagen Wound Healing Center, Bispebjerg Hospital, Copenhagen, Denmark

IWGDF

Guidelines

Position: MD, Consultant

IWGDF Working Group: Offloading

For the following items, please disclose any interest from the past five years that might be perceived by others as potentially influencing your judgment in any topic in the IWGDF Guideline(s) that you contribute to.

- Ancillary positions: Steno Diabetes Center Copenhagen, Orthopedic consultant

- Personal financial interests:

Do you have personal financial interests such as stocks and shares? If yes, please declare:

• Shares in SoftOx Solutions AB. Partial holder of patent for antimicrobial topical solution.

Do you have personally received finances, funding for an account that you benefit from financially or professionally, for honorary fees or consultancy? If yes, please declare:

- Consultancy fees from: SoftOx Solutions AB, Bayer Pharmaceuticals, Mölnlycke AB, Coloplast A/S, Novo Nordisk A/S, AstraZeneca A/S
- <u>- Personal relations</u> (this includes personal relations or relations via close family that might be perceived by others as potentially influencing your judgment):
 - None
- <u>- Externally funded research</u> (this includes research funding awarded to you as project member, or to your department, for funding that might be perceived by others as potentially influencing your judgment). If yes, name the title/topic of the grant.
 - Eurostars EU Fund, E114468 SuTBA, Wound Laser Treatment
 - Danish Innovation Fund, Inno-booster, 360 Degree Health, Data Integration and Analysis –digital tools for continuous and coherent personalized treatment and empowerment.
 - Novo Nordisk Foundation, "Chronic non-cancer pain issues in Denmark: epidemiological aspects, prevention and intervention",
 - Eurostars EU Fund, "Chronic non-cancer pain issues in Denmark: epidemiological aspects, prevention and intervention",

- Other disclosures:

Signature and date:

Copenhagen, March 20, 2022